Cerebral VasospasmNCT01595802
Non-Significant Risk Study Comparing the Nautilus NeuroWaveTM to Transcranial Doppler as an Aid to Diagnosing Vasospasm
An observational study of Cerebral Vasospasm, run by Jan Medical, Inc. at 1 site in United States.
Trial summary
The purpose of the study is to determine the sensitivity, specificity and predictive values of the Jan Medical NeuroWave System in detecting moderate and severe vasospasm in comparison to Trans Cranial Doppler(TCD). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cerebral Vasospasm
- What is being tested?
- Nautilus NeuroWave and Transcranial Doppler (TCD)
- Type of treatment
- Medical device
- How many people
- 92 participants
- Where
- 1 siteUnited States
- Study dates
- Jan 2012to Jul 2015
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: 1. Male or female subjects 18 years of age or older. 2. Subjects with subarachnoid hemorrhage who are receiving clinical and diagnostic surveillance for vasospasm.
Who may be able to join
- Male or female subjects 18 years of age or older.
- Subjects with subarachnoid hemorrhage who are receiving clinical and diagnostic surveillance for vasospasm.
- Signed informed consent from the patient or the patient's Legally Authorized Representative
Who cannot join
- Unstable medical illness such that recordings might interfere with medical care.
- Presence of head bandages or brain monitors that might physically interfere with the tested recording device.
- Current hemicraniectomy.
- Subjects who are not candidates for Transcranial Doppler assessment
Trial locations and contacts
1 site in 1 country.
United States1 site
University of California San Francisco (UCSF)
San Francisco, California, 94142-0114
About this study
Official title: A Non-Randomized, Non-Significant Risk Study Comparing the Nautilus NeuroWaveTM System to Transcranial Doppler as an Aid to Diagnosing Vasospasm
The purpose of the study is to determine the sensitivity, specificity and predictive values of the Jan Medical NeuroWave System in detecting moderate and severe vasospasm in comparison to Trans Cranial Doppler(TCD).
Read the detailed description
Cerebral vasospasm generally occurs due to a ruptured brain aneurysm, or (very rarely) hemorrhage from another blood vessel abnormality such as an arteriovenous malformation (AVM). The common factor is the abnormal presence of a substantial amount of blood on the outer ("subarachnoid" or "adventitial") surface of the blood vessel. This can particularly affect arteries at the base of the brain, i.e., around the Circle of Willis.
Depending on the severity, this can be seen using conventional angiography. Angiographic spasm tends to be most readily detected at about 5-7 days after the SAH, although it may be detected as early as 3 days after the hemorrhage. It occurs in between half to two-thirds of all aneurysm patients depending on the time at which angiography was carried out. Clinical vasospasm occurs in approximately one-third of all patients suffering aneurysmal SAH.
The essential problem with vasospasm is that it causes an artery to reduce blood flow or completely shut down. As a result, the part of the brain formerly supplied by that artery effectively starves (ischemia) and may die (infarction or stroke). Overall, cerebral vasospasm accounts for approximately 20% of the severe disability and death associated with ruptured aneurysms.
If vasospasm is detected early, a patient can be treated with balloon angioplasty to reopen the vessels or have infusions of a vasodilator administered (typically verapamil or nicardipine). Alternatively, or in concert with that treatment, one can administer intravenous drugs that raise the patient's blood pressure ("pressors") to force more blood through the narrow arteries. Both of these treatments carry risk and therefore should not be administered unless vasospasm is detected. Therefore, in order to prevent this form of brain injury and enhance the likelihood that a patient will do better, one needs to detect vasospasm before it becomes severe enough to injure the brain.
Vasospasm can be detected by the signs observed on physical examination of the patient and by radiological methods such as cerebral angiography, and Trans-Cranial Doppler (TCD) ultrasound. The physical exam is sensitive for vasospasm in patients who are otherwise awake and able to participate in a neurological examination. Many patients with subarachnoid hemorrhage are not keenly aware nor participative to make this clinical exam meaningful. Therefore clinical examination alone lacks sensitivity.
The gold standard method for detecting vasospasm is cerebral angiography. This involves injection of a radiopaque dye into the arterial blood stream of a patient and when the dye reaches the brain X-rays are taken. Although this is the gold-standard for diagnosing vasospasm it carries the risk of arterial injury or even stroke, and the expense is high. In addition the contrast dye used in these studies carries the risk of renal failure. As a result, this technology is generally employed once vasosapasm is suspected from a Trans Cranial Doppler (TCD) study.
TCD is a bedside test that relies on ultrasound waves generated from a probe placed on the skin of the head and/or neck region to detect the flow of blood in a cerebral artery. It is a convenient, safe, and frequently effective method that can be used to rapidly confirm the clinical findings, and is much less invasive than cerebral angiography. It has, however, numerous technical limitations; for example, one can only detect vasospasm in the proximal vessels of the circle of Willis and therefore lacks sensitivity. It is also quite operator dependent and limited to patients with appropriate skull thickness and acoustic windows.
What is needed is a non-invasive, user independent, safe method to detect cerebral vasospasm before it causes brain injury. The technology needs to be simple to use and can be done at the bedside in an ICU environment. Such a tool will likely improve patient outcome by initiating a chain of events that can mitigate vasospasm (cerebral angioplasty or initiation of vasopressor therapy) and will likely shorten the length of stay within the Neuro ICU saving hospitals money.
The Jan Medical NeuroWave is a simple, rapid, non invasive aid to the diagnosis of vasospasm that is not operator dependent nor limited by skull structure. This study will determine the sensitivity, specificity and predictive values of the Jan Medical NeuroWave System in detecting moderate and severe vasospasm in comparison to Trans Cranial Doppler (TCD).
- Conditions
- Cerebral Vasospasm
- Being tested
- Nautilus NeuroWave, Transcranial Doppler (TCD)
- Keywords
- Cerebral vasospasm
- Medical subject headings
- Vasospasm, Intracranial
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nautilus NeuroWaveDevice
The Nautilus NeuroWave device will be utilized on subjects with sub-arachnoid hemorrhage that undergo TCD measurements to diagnose Vasospasm. A recording will be obtained using the device each time a TCD measurement is made.
In this intervention, patients are recorded using the Nautilus Neurowave device.
Transcranial Doppler (TCD)Device
Subjects with sub-arachnoid hemorrhage undergo TCD measurements to diagnose Vasospasm. Patients that were detected to have a vasospasm using TCD will also be classified as having mild, moderate and severe vasospasm.
| Study group | Role | What they receive |
|---|---|---|
| Subjects without Vasospasm | Transcranial Doppler (TCD) will be used to evaluate if subject has a vasospasm. Intervention with Nautilus NeuroWave recording to obtain baseline status. Receives: Device: Nautilus NeuroWave; Device: Transcranial Doppler (TCD) | |
| Subjects with Vasospasm | Transcranial Doppler (TCD) will be used to evaluate if subject has a vasospasm. If confirmed by TCD, the degree of vasospasm will also be evaluated and classified as mild, moderate and severe Vasospasm.
Intervention with Nautilus NeuroWave recording to obtain recordings with mild, moderate and severe Vasospasm. Receives: Device: Nautilus NeuroWave; Device: Transcranial Doppler (TCD) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sensitivity and specificity as a diagnostic aid in detecting vasospasm in subarachnoid hemorrhage
Outcome determine Upon completion of study and unmaksing
Measured: 12 months
Secondary outcomes (2)
Location of vasospasm in the caranium
outcome determine upon completion of study and unmasking
Measured: 12 months
Incidence of device related adverse events
outcome determine upon completion of study and unmasking
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 May 2012 (estimated)
- Study startJan 2012
- Primary completionJul 2013
- Study completionJul 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cerebral VasospasmStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 92 participants (actual)
Sponsor and investigators
- Lead sponsor
- Jan Medical, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Wade Smith, M.D, PH.D., Principal investigator, University of California, San Francisco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01595802
- Sponsor's protocol ID
- DC1B-01
- Status last verified
- Jun 2022
- First submitted
- 14 Feb 2012
- Last updated
- 9 Jun 2022
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Jun 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Non-Randomized, Non-Significant Risk Study Comparing the Nautilus NeuroWaveTM System to Transcranial Doppler as an Aid to Diagnosing Vasospasm
- ClinicalTrials.gov ID
- NCT01595802
- Acronym / sponsor ID
- DC1B-01
- Conditions
- Cerebral Vasospasm
- Keywords
- Cerebral vasospasm
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 92 participants (actual)
- Lead sponsor
- Jan Medical, Inc.Industry (pharma, biotech, devices)
- Study start
- Jan 2012
- Primary completion
- Jul 2013 (actual)
- Study completion
- Jul 2015 (actual)
- First posted
- 10 May 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is to determine the sensitivity, specificity and predictive values of the Jan Medical NeuroWave System in detecting moderate and severe vasospasm in comparison to Trans Cranial Doppler(TCD).
Detailed description
Cerebral vasospasm generally occurs due to a ruptured brain aneurysm, or (very rarely) hemorrhage from another blood vessel abnormality such as an arteriovenous malformation (AVM). The common factor is the abnormal presence of a substantial amount of blood on the outer ("subarachnoid" or "adventitial") surface of the blood vessel. This can particularly affect arteries at the base of the brain, i.e., around the Circle of Willis.
Depending on the severity, this can be seen using conventional angiography. Angiographic spasm tends to be most readily detected at about 5-7 days after the SAH, although it may be detected as early as 3 days after the hemorrhage. It occurs in between half to two-thirds of all aneurysm patients depending on the time at which angiography was carried out. Clinical vasospasm occurs in approximately one-third of all patients suffering aneurysmal SAH.
The essential problem with vasospasm is that it causes an artery to reduce blood flow or completely shut down. As a result, the part of the brain formerly supplied by that artery effectively starves (ischemia) and may die (infarction or stroke). Overall, cerebral vasospasm accounts for approximately 20% of the severe disability and death associated with ruptured aneurysms.
If vasospasm is detected early, a patient can be treated with balloon angioplasty to reopen the vessels or have infusions of a vasodilator administered (typically verapamil or nicardipine). Alternatively, or in concert with that treatment, one can administer intravenous drugs that raise the patient's blood pressure ("pressors") to force more blood through the narrow arteries. Both of these treatments carry risk and therefore should not be administered unless vasospasm is detected. Therefore, in order to prevent this form of brain injury and enhance the likelihood that a patient will do better, one needs to detect vasospasm before it becomes severe enough to injure the brain.
Vasospasm can be detected by the signs observed on physical examination of the patient and by radiological methods such as cerebral angiography, and Trans-Cranial Doppler (TCD) ultrasound. The physical exam is sensitive for vasospasm in patients who are otherwise awake and able to participate in a neurological examination. Many patients with subarachnoid hemorrhage are not keenly aware nor participative to make this clinical exam meaningful. Therefore clinical examination alone lacks sensitivity.
The gold standard method for detecting vasospasm is cerebral angiography. This involves injection of a radiopaque dye into the arterial blood stream of a patient and when the dye reaches the brain X-rays are taken. Although this is the gold-standard for diagnosing vasospasm it carries the risk of arterial injury or even stroke, and the expense is high. In addition the contrast dye used in these studies carries the risk of renal failure. As a result, this technology is generally employed once vasosapasm is suspected from a Trans Cranial Doppler (TCD) study.
TCD is a bedside test that relies on ultrasound waves generated from a probe placed on the skin of the head and/or neck region to detect the flow of blood in a cerebral artery. It is a convenient, safe, and frequently effective method that can be used to rapidly confirm the clinical findings, and is much less invasive than cerebral angiography. It has, however, numerous technical limitations; for example, one can only detect vasospasm in the proximal vessels of the circle of Willis and therefore lacks sensitivity. It is also quite operator dependent and limited to patients with appropriate skull thickness and acoustic windows.
What is needed is a non-invasive, user independent, safe method to detect cerebral vasospasm before it causes brain injury. The technology needs to be simple to use and can be done at the bedside in an ICU environment. Such a tool will likely improve patient outcome by initiating a chain of events that can mitigate vasospasm (cerebral angioplasty or initiation of vasopressor therapy) and will likely shorten the length of stay within the Neuro ICU saving hospitals money.
The Jan Medical NeuroWave is a simple, rapid, non invasive aid to the diagnosis of vasospasm that is not operator dependent nor limited by skull structure. This study will determine the sensitivity, specificity and predictive values of the Jan Medical NeuroWave System in detecting moderate and severe vasospasm in comparison to Trans Cranial Doppler (TCD).
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Subjects without Vasospasm | – | Device: Nautilus NeuroWave, Device: Transcranial Doppler (TCD)Transcranial Doppler (TCD) will be used to evaluate if subject has a vasospasm. Intervention with Nautilus NeuroWave recording to obtain baseline status. |
| Subjects with Vasospasm | – | Device: Nautilus NeuroWave, Device: Transcranial Doppler (TCD)Transcranial Doppler (TCD) will be used to evaluate if subject has a vasospasm. If confirmed by TCD, the degree of vasospasm will also be evaluated and classified as mild, moderate and severe Vasospasm. Intervention with Nautilus NeuroWave recording to obtain recordings with mild, moderate and severe Vasospasm. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- 1. Male or female subjects 18 years of age or older. 2. Subjects with subarachnoid hemorrhage who are receiving clinical and diagnostic surveillance for vasospasm.
Key inclusion criteria (3 listed)
- Male or female subjects 18 years of age or older.
- Subjects with subarachnoid hemorrhage who are receiving clinical and diagnostic surveillance for vasospasm.
- Signed informed consent from the patient or the patient's Legally Authorized Representative
Key exclusion criteria (4 listed)
- Unstable medical illness such that recordings might interfere with medical care.
- Presence of head bandages or brain monitors that might physically interfere with the tested recording device.
- Current hemicraniectomy.
- Subjects who are not candidates for Transcranial Doppler assessment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nautilus NeuroWaveThe Nautilus NeuroWave device will be utilized on subjects with sub-arachnoid hemorrhage that undergo TCD measurements to diagnose Vasospasm. A recording will be obtained using the device each time a TCD measurement is made. In this intervention, patients are recorded using the Nautilus Neurowave device. | Device | Subjects with Vasospasm, Subjects without Vasospasm |
| Transcranial Doppler (TCD)Subjects with sub-arachnoid hemorrhage undergo TCD measurements to diagnose Vasospasm. Patients that were detected to have a vasospasm using TCD will also be classified as having mild, moderate and severe vasospasm. | Device | Subjects with Vasospasm, Subjects without Vasospasm |
Primary outcome
Sensitivity and specificity as a diagnostic aid in detecting vasospasm in subarachnoid hemorrhage
Time frame: 12 months
Outcome determine Upon completion of study and unmaksing
2 secondary outcomes
Location of vasospasm in the caranium
Time frame: 12 months
Incidence of device related adverse events
Time frame: 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jun 2022.
- Individual participant dataSharing planned: No
Related trials for Cerebral Vasospasm
Not yet recruiting
Endovascular Therapy for Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Hemorrhage, Aneurysmal, Cerebral Vasospasm After Subarachnoid Hemorrhage
Not yet recruiting
Noninvasive CA Monitoring Validation and Autonomic Modulation in Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Hemorrhage, Aneurysmal, Delayed Cerebral Ischemia
Recruiting
The Effect of Transcutaneous Vagal Nerve Stimulation (tVNS) on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid Hemorrhage
Aneurysmal Subarachnoid Hemorrhage, Vasospasm, Cerebral
RecruitingObservational study
Nitric Oxide Consumption as a Predictor of Vasospasm in Subarachnoid Hemorrhage
Aneurysmal Subarachnoid Hemorrhage, Cerebral Vasospasm
RecruitingObservational study
Registry on NeVa VS for CerebraL VAsospasm ManagemenT in Post SAH PatiEnts
Cerebral Vasospasm, Aneurysmal Subarachnoid Hemorrhage (aSAH)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Wade Smith, M.D, PH.D. principal investigator
University of California, San Francisco
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cerebral Vasospasm, run by Jan Medical, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Jun 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sensitivity and specificity as a diagnostic aid in detecting vasospasm in subarachnoid hemorrhage (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jun 2022; AzTrials last refreshed its copy on 3 Nov 2026.